Shopping Cart 0
Cart Subtotal
USD 0

La Jolla Pharmaceutical Company (LJPC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company's major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company (LJPC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13

La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14

Licensing Agreements 15

La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15

IURTC Enters into Licensing Agreement with La Jolla Pharma 16

IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17

La Jolla Pharma Enters into Licensing Agreement with George Washington University 18

La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19

Equity Offering 20

La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20

La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21

La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23

La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24

La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26

La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28

La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29

La Jolla Pharmaceutical Company-Key Competitors 30

La Jolla Pharmaceutical Company-Key Employees 31

La Jolla Pharmaceutical Company-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Oct 24, 2018: La Jolla Pharmaceutical Company Reports Financial Results for the Three and Nine Months Ended September 30, 2018 33

Aug 08, 2018: La Jolla Pharmaceutical company announces financial results for the three and six months ended June 30, 2018 and recent corporate progress 34

May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 35

Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 37

Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 38

Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 39

Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 40

Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 41

Product News 42

09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13

La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14

La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15

IURTC Enters into Licensing Agreement with La Jolla Pharma 16

IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17

La Jolla Pharma Enters into Licensing Agreement with George Washington University 18

La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19

La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20

La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21

La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23

La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24

La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26

La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28

La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29

La Jolla Pharmaceutical Company, Key Competitors 30

La Jolla Pharmaceutical Company, Key Employees 31

La Jolla Pharmaceutical Company, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

La Jolla Pharmaceutical Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

La Jolla Pharmaceutical Company (La Jolla) is a biopharmaceutical company that discovers, develops and commercializes pharmaceutical products for life threatening diseases. The company's major product includes Giapreza, an injection for intravenous infusion indicated to increase blood pressure in adults with septic or other distributive shock. Its clinical-stage investigational product includes LJPC-401, a formulation of synthetic human hepcidin intended for the treatment of iron overload, such as hereditary hemochromatosis, sickle cell disease, beta thalassemia and myelodysplastic syndrome. The company distributes its products through a network of specialty distributors to hospitals across the US. La Jolla is headquartered in San Diego, California, the US.

La Jolla Pharmaceutical Company (LJPC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deal Details 13

Asset Purchase 13

La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13

La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14

Licensing Agreements 15

La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15

IURTC Enters into Licensing Agreement with La Jolla Pharma 16

IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17

La Jolla Pharma Enters into Licensing Agreement with George Washington University 18

La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19

Equity Offering 20

La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20

La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21

La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23

La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24

La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26

La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28

La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29

La Jolla Pharmaceutical Company-Key Competitors 30

La Jolla Pharmaceutical Company-Key Employees 31

La Jolla Pharmaceutical Company-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Oct 24, 2018: La Jolla Pharmaceutical Company Reports Financial Results for the Three and Nine Months Ended September 30, 2018 33

Aug 08, 2018: La Jolla Pharmaceutical company announces financial results for the three and six months ended June 30, 2018 and recent corporate progress 34

May 10, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2018 and Recent Corporate Progress 35

Feb 22, 2018: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Twelve Months Ended December 31, 2017 and Recent Corporate Progress 37

Oct 26, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Nine Months Ended September 30, 2017 and Recent Corporate Progress 38

Jul 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate Progress 39

Apr 27, 2017: La Jolla Pharmaceutical Company Announces Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate Progress 40

Feb 23, 2017: La Jolla Pharmaceutical Company Announces Fourth Quarter and Full Year 2016 Financial Results and Corporate Progress 41

Product News 42

09/13/2017: Researchers Develop New Strategy to Target KRAS Mutant Cancer 42

Appendix 43

Methodology 43

About GlobalData 43

Contact Us 43

Disclaimer 43


List Of Figure

List of Figures

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Key Facts, 2017 2

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

La Jolla Pharmaceutical Company, Deals By Therapy Area, 2012 to YTD 2018 9

La Jolla Pharmaceutical Company, Medical Devices Deals, 2012 to YTD 2018 10

La Jolla Pharmaceutical Company, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

La Jolla Pharma to Acquire Rights to Gentamicin Derivatives from IURTC 13

La Jolla Pharma Acquires GCS-100 From Solana Therapeutics 14

La Jolla Pharma Enters into Licensing Agreement with Vanderbilt University 15

IURTC Enters into Licensing Agreement with La Jolla Pharma 16

IURTC and University of Alabama at Birmingham Enter into Licensing Agreement with La Jolla Pharma 17

La Jolla Pharma Enters into Licensing Agreement with George Washington University 18

La Jolla Pharma Enters Into Option For Licensing Agreement With George Washington University 19

La Jolla Pharma Files Registration Statement for USD150 Million in Public Offering 20

La Jolla Pharmaceutical Raises USD125 Million in Underwritten Public Offering of Shares 21

La Jolla Pharma Prices Public Offering of Shares for USD100 Million 23

La Jolla Pharma Raises USD111.4 Million in Public Offering of Shares 24

La Jolla Pharma Raises USD56.6 Million in Public Offering of Shares 26

La Jolla Pharma Completes Private Placement Of Shares For USD 6.7 Million 28

La Jolla Pharma Completes Private Placement Of Preferred Stock For USD 3.3 Million 29

La Jolla Pharmaceutical Company, Key Competitors 30

La Jolla Pharmaceutical Company, Key Employees 31

La Jolla Pharmaceutical Company, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

La Jolla Pharmaceutical Company, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.